These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 27385486)
1. Mutant p53 and mTOR/PKM2 regulation in cancer cells. Dando I; Cordani M; Donadelli M IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486 [TBL] [Abstract][Full Text] [Related]
2. Double mutant P53 (N340Q/L344R) promotes hepatocarcinogenesis through upregulation of Pim1 mediated by PKM2 and LncRNA CUDR. Wu M; An J; Zheng Q; Xin X; Lin Z; Li X; Li H; Lu D Oncotarget; 2016 Oct; 7(41):66525-66539. PubMed ID: 27167190 [TBL] [Abstract][Full Text] [Related]
3. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis. Tao T; Su Q; Xu S; Deng J; Zhou S; Zhuang Y; Huang Y; He C; He S; Peng M; Hocher B; Yang X J Cell Physiol; 2019 Mar; 234(3):3088-3104. PubMed ID: 30221356 [TBL] [Abstract][Full Text] [Related]
4. The mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma. Xiaoyu H; Yiru Y; Shuisheng S; Keyan C; Zixing Y; Shanglin C; Yuan W; Dongming C; Wangliang Z; Xudong B; Jie M Technol Cancer Res Treat; 2018 Jan; 17():1533033818780063. PubMed ID: 29916308 [TBL] [Abstract][Full Text] [Related]
5. Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1. He CL; Bian YY; Xue Y; Liu ZX; Zhou KQ; Yao CF; Lin Y; Zou HF; Luo FX; Qu YY; Zhao JY; Ye ML; Zhao SM; Xu W Sci Rep; 2016 Feb; 6():21524. PubMed ID: 26876154 [TBL] [Abstract][Full Text] [Related]
6. Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells. Cheng K; Hao M Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916907 [TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Sun Q; Chen X; Ma J; Peng H; Wang F; Zha X; Wang Y; Jing Y; Yang H; Chen R; Chang L; Zhang Y; Goto J; Onda H; Chen T; Wang MR; Lu Y; You H; Kwiatkowski D; Zhang H Proc Natl Acad Sci U S A; 2011 Mar; 108(10):4129-34. PubMed ID: 21325052 [TBL] [Abstract][Full Text] [Related]
8. PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer. Zhu H; Wu J; Zhang W; Luo H; Shen Z; Cheng H; Zhu X Sci Rep; 2016 Aug; 6():30788. PubMed ID: 27492148 [TBL] [Abstract][Full Text] [Related]
9. Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells. Zhou Z; Li M; Zhang L; Zhao H; Şahin Ö; Chen J; Zhao JJ; Songyang Z; Yu D Cancer Res; 2018 May; 78(9):2248-2261. PubMed ID: 29440169 [TBL] [Abstract][Full Text] [Related]
10. Distinctive role of SIK1 and SIK3 isoforms in aerobic glycolysis and cell growth of breast cancer through the regulation of p53 and mTOR signaling pathways. Ponnusamy L; Manoharan R Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118975. PubMed ID: 33545220 [TBL] [Abstract][Full Text] [Related]
11. Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells. Cordani M; Butera G; Pacchiana R; Masetto F; Mullappilly N; Riganti C; Donadelli M Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111081 [TBL] [Abstract][Full Text] [Related]
12. The multifaceted regulation and functions of PKM2 in tumor progression. Li Z; Yang P; Li Z Biochim Biophys Acta; 2014 Dec; 1846(2):285-96. PubMed ID: 25064846 [TBL] [Abstract][Full Text] [Related]
13. PKM2 coordinates glycolysis with mitochondrial fusion and oxidative phosphorylation. Li T; Han J; Jia L; Hu X; Chen L; Wang Y Protein Cell; 2019 Aug; 10(8):583-594. PubMed ID: 30887444 [TBL] [Abstract][Full Text] [Related]
14. PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells. Jiang Y; Wang Y; Wang T; Hawke DH; Zheng Y; Li X; Zhou Q; Majumder S; Bi E; Liu DX; Huang S; Lu Z Nat Commun; 2014 Nov; 5():5566. PubMed ID: 25412762 [TBL] [Abstract][Full Text] [Related]
15. PKM2, cancer metabolism, and the road ahead. Dayton TL; Jacks T; Vander Heiden MG EMBO Rep; 2016 Dec; 17(12):1721-1730. PubMed ID: 27856534 [TBL] [Abstract][Full Text] [Related]
16. Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. Cordani M; Oppici E; Dando I; Butturini E; Dalla Pozza E; Nadal-Serrano M; Oliver J; Roca P; Mariotto S; Cellini B; Blandino G; Palmieri M; Di Agostino S; Donadelli M Mol Oncol; 2016 Aug; 10(7):1008-29. PubMed ID: 27118659 [TBL] [Abstract][Full Text] [Related]
17. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599 [TBL] [Abstract][Full Text] [Related]
18. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Nemazanyy I; Espeillac C; Pende M; Panasyuk G Biochem Soc Trans; 2013 Aug; 41(4):917-22. PubMed ID: 23863156 [TBL] [Abstract][Full Text] [Related]
19. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway. Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097 [TBL] [Abstract][Full Text] [Related]
20. Changes in PKM2 associate with prostate cancer progression. Wong N; Yan J; Ojo D; De Melo J; Cutz JC; Tang D Cancer Invest; 2014 Aug; 32(7):330-8. PubMed ID: 24884829 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]